Asher Holzer
Co-founder & Chairman
Claimed by owner PsyRx
Former names:
Drug Development Using Biological Bioreactor Technology
PsyRx
www.prnewswire.com
•
Feb 22, 2022
PsyRx Announces Appointment of Prof. Itamar Grotto as New Executive Chairman of the Board
www.jpost.com
•
Feb 9, 2022
https://www.jpost.com/health-and-wellness/mind-and-spirit/article-695925
www.israel21c.org
•
Jan 3, 2022
Now psychedelics are coming to your medicine cabinet
www.maariv.co.il
•
Sep 3, 2021
חברה ישראלית מפתחת תרופות חדשות לטיפול בדיכאון עם מרכיב מפתיע
www.jpost.com
•
Jul 12, 2021
https://www.jpost.com/health-science/israeli-lab-grows-magic-mushrooms-to-treat-depression-673524
About
PsyRx is a pharmaceutical R&D company developing biological API psilocybin and ibogaine in accordance with GMP standards. Using biological bioreactor technology, the company is focused on becoming a leading producer of GMP-standard ibogaine and psilocybin for use by target customers in the development and production of psychedelic- and ibogaine-based pharmaceuticals, food supplements, and other products.
PsyRx also aims to develop a revolutionary antidepressant drug based on a combination of ibogaine and existing approved antidepressants, with a focus on reducing side effects and improving efficacy. The companys vision is to develop new drugs for the treatment of depression and addiction by using existing regulatory-approved antidepressant drug formulations with ibogaine.
Ibogaine is also known to affect the brain much like antidepressants, but through different pathways. Therefore, PsyRx believes that there might be synergy between these two drugs, enabling them to treat depression with better efficacy and fewer side effects than existing antidepressants.
PsyRx also aims to develop a revolutionary antidepressant drug based on a combination of ibogaine and existing approved antidepressants, with a focus on reducing side effects and improving efficacy. The companys vision is to develop new drugs for the treatment of depression and addiction by using existing regulatory-approved antidepressant drug formulations with ibogaine.
Ibogaine is also known to affect the brain much like antidepressants, but through different pathways. Therefore, PsyRx believes that there might be synergy between these two drugs, enabling them to treat depression with better efficacy and fewer side effects than existing antidepressants.
Employees
Product stage
Primary Sector
Life Sciences & HealthTech
Products
-
Geographic markets
-
Funding
Total Funding
Undisclosed
Last Funding
Undisclosed
Funding Stage
Total Rounds
0
Investors
0
News
(5)
www.prnewswire.com
•
Feb 22, 2022
PsyRx Announces Appointment of Prof. Itamar Grotto as New Executive Chairman of the Board
www.jpost.com
•
Feb 9, 2022
https://www.jpost.com/health-and-wellness/mind-and-spirit/article-695925
www.israel21c.org
•
Jan 3, 2022
Now psychedelics are coming to your medicine cabinet
www.maariv.co.il
•
Sep 3, 2021
חברה ישראלית מפתחת תרופות חדשות לטיפול בדיכאון עם מרכיב מפתיע
www.jpost.com
•
Jul 12, 2021
https://www.jpost.com/health-science/israeli-lab-grows-magic-mushrooms-to-treat-depression-673524
The Team
(4)
AH
Itay Hecht
Co-founder & CEO
KB
Kobi Buxdorf
Co-founder & CTO
NB
Noam Barnea-Ygael
Research Officer
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Others
Academic Techonology
Oct 2019
undefined
Method for In-vitro manufacturing secondary metabolites in inboga root suspension and psilocybin suspension bioreactor
Media gallery
(0)Locations
Israel
Tel Aviv, Israel
Locations
Israel
Tel Aviv, Israel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,